With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

According to TipRanks.com, Richter is a 4-star analyst with an average return of 8.8% and a 42.9% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ultragenyx ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Multiple Massachusetts-based vaccine companies, including Moderna, are affected by U.S. Health and Human Services Secretary ...

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

The Trump administration says it is pulling half a billion dollars from U.S. government-funded research projects to create ...

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

Health Secretary Robert F. Kennedy Jr.’s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding ...

Neither UTMB nor Moderna has confirmed the nature of the project included in the announcement, or how much funding is being ...